The Tumor Microenvironment in Large B-cell Lymphoma: Cellular Ecosystems, Spatial Organization, and Therapeutic Implications

Large B-cell lymphomas (LBCLs) comprise biologically heterogeneous malignancies whose clinical behavior reflects interactions between malignant B cells and their surrounding immune and stromal compartments. Single-cell sequencing, spatial transcriptomics, and multiplex imaging have revealed distinct microenvironmental ecosystems that conventional measures of immune-cell abundance cannot adequately characterize. These approaches identify heterogeneous T-cell states, macrophage-rich niches, disrupted lymphoid architecture, and stromal programs associated with immune exclusion and treatment response. Tumor-intrinsic genetic and epigenetic alterations further influence antigen presentation, cytokine signaling, and interactions with the microenvironment. However, spatial proximity and transcriptional signatures do not necessarily establish functional interactions, and the prognostic relevance of individual cell populations varies across cohorts, anatomical sites, and treatment settings. Although emerging microenvironmental classifications offer opportunities to refine risk stratification and investigate resistance to immunochemotherapy, bispecific antibodies, and chimeric antigen receptor T-cell therapy, most require prospective validation before clinical implementation. This review critically examines the cellular composition, spatial organization, and molecular regulation of the LBCL microenvironment, alongside the strengths and limitations of current profiling technologies. Particular attention is given to the distinction between descriptive cellular atlases and experimentally validated mechanisms, the influence of tumor subtype and treatment context, and opportunities to develop clinically feasible biomarkers. Integrating longitudinal sampling, functional studies, and standardized spatial analyses may help establish which microenvironmental features can reliably guide therapeutic selection and the development of targeted combinations.

Authors

Publication Details

Journal
Cancer Biome and Targeted Therapy
Published
2026-11-14
DOI
https://doi.org/10.66505/cbtt.v1i4.57
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Tumor Microenvironment in Large B-cell Lymphoma: Cellular Ecosystems, Spatial Organization, and Therapeutic Implications

Alexander J. A. Deutsch, Katrin Pansy, Antonella Zupo, Matthias Zanker
Cancer Biome and Targeted Therapy
Lymphoma Diagnosis and Treatment
article

The Tumor Microenvironment in Large B-cell Lymphoma: Cellular Ecosystems, Spatial Organization, and Therapeutic Implications

Alexander J. A. Deutsch, Katrin Pansy, Antonella Zupo, Matthias Zanker
article en

Abstract

Large B-cell lymphomas (LBCLs) comprise biologically heterogeneous malignancies whose clinical behavior reflects interactions between malignant B cells and their surrounding immune and stromal compartments. Single-cell sequencing, spatial transcriptomics, and multiplex imaging have revealed distinct microenvironmental ecosystems that conventional measures of immune-cell abundance cannot adequately characterize. These approaches identify heterogeneous T-cell states, macrophage-rich niches, disrupted lymphoid architecture, and stromal programs associated with immune exclusion and treatment response. Tumor-intrinsic genetic and epigenetic alterations further influence antigen presentation, cytokine signaling, and interactions with the microenvironment. However, spatial proximity and transcriptional signatures do not necessarily establish functional interactions, and the prognostic relevance of individual cell populations varies across cohorts, anatomical sites, and treatment settings. Although emerging microenvironmental classifications offer opportunities to refine risk stratification and investigate resistance to immunochemotherapy, bispecific antibodies, and chimeric antigen receptor T-cell therapy, most require prospective validation before clinical implementation. This review critically examines the cellular composition, spatial organization, and molecular regulation of the LBCL microenvironment, alongside the strengths and limitations of current profiling technologies. Particular attention is given to the distinction between descriptive cellular atlases and experimentally validated mechanisms, the influence of tumor subtype and treatment context, and opportunities to develop clinically feasible biomarkers. Integrating longitudinal sampling, functional studies, and standardized spatial analyses may help establish which microenvironmental features can reliably guide therapeutic selection and the development of targeted combinations.

Cancer Biome and Targeted Therapy
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon